Recap Of Tuesday’s Biotech Catalysts – End Of the Day Summary
Amgen (NASDAQ:AMGN) announced top-line results from the global Phase 3 CodeBreaK 200 trial evaluating once daily oral LUMAKRAS (sotorasib)…
Jounce Therapeutics Shares Fall After Disappointing Mid-Stage Lung Cancer Trial Data
Jounce Therapeutics Inc (NASDAQ:JNCE) reported topline data from the randomized Phase 2 SELECT trial evaluating vopratelimab, combined with pimivalimab in immunotherapy…
Benzinga Pro’s Top 5 Stocks To Watch For Tuesday, August 30, 2022: BBBY, CONN, OLB, MGAM, JNCE
Showcasing Benzinga Pro's Movers and News tools!
The following stocks were identified using Benzinga Pro's Movers tool; the News tool was used to check for a news catalyst.
Bed Bath & Beyond (BBBY) - The
Jounce Therapeutics Reports Results From Phase 2 Randomized SELECT Trial Testing 2 Different Doses Of Vopratelimab In TISvopra Biomarker-Selected Patients; Co. Reports Study Did Not Meet Its Primary Endpoint
- SELECT trial of vopratelimab in combination with pimivalimab versus pimivalimab alone did not meet its primary endpoint of mean tumor change averaged over 9 and 18 weeks -
- Encouraging trends in improved mean tumor
Earnings Scheduled For August 4, 2022
Companies Reporting Before The Bell
• Toyota Motor (NYSE:TM) is projected to report earnings for its first quarter.
Stocks That Hit 52-Week Lows On Thursday
During the Thursday's session, 100 stocks hit new 52-week lows.
4 Analysts Have This to Say About Jounce Therapeutics
Jounce Therapeutics (NASDAQ:JNCE) has observed the following analyst ratings within the last quarter:
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 807 companies reached new 52-week lows.